January 21, 2026 06:50 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Twist before Tamil Nadu polls! TTV Dhinakaran returns to NDA after bitter exit | Gold goes berserk! Prices smash all-time high as global tensions explode | Markets end in red: Sensex slips 271 points, Nifty below 25,200; rupee hits record low | Nitin Nabin becomes BJP’s youngest president ahead of key assembly polls, PM Modi calls him ‘my boss’ | Viral video scandal rocks Karnataka Police: DGP Ramachandra Rao suspended | Jolt to ECI over SIR! SC allows BLAs at hearing, questions 'logical discrepancy'; TMC declares 'BJP's game over' | Will dal disrupt diplomacy? US lawmakers urge Trump to act on India’s 30% pulse tariff | 'Pakistan deserves Operation Sindoor 2.0', says Baloch leader over Trump’s Gaza board invitation to Islamabad | From Malda to the nation: PM Modi unveils India’s Vande Bharat sleeper | War zone Beldanga: Highway blocked, reporters attacked in migrant death protests
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.